Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

150 ARTÍCULOS , VIENDO DEL 46 AL 60

Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, Nobili F, Ratib O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:183-195. doi: 10.1016/j.neurobiolaging.2016.03.033.

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Mattsson N, Lönneborg A, Boccardi M, Blennow K, Hansson O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:196-213. doi: 10.1016/j.neurobiolaging.2016.02.034.

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, Garibotto V, Herholz K, Nobili F, Nordberg A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:214-227. doi: 10.1016/j.neurobiolaging.2016.07.012.

Clinical validity of presynaptic dopaminergic imaging with (123)I-ioflupane and noradrenergic imaging with (123)I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework

Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, Varrone A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

Neurobiol Aging. 2017 Apr;52:228-242. doi: 10.1016/j.neurobiolaging.2016.04.026.

Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease

Kang S, Lee YH, Lee JE.

Yonsei Med J. 2017 May;58(3):479-488. doi: 10.3349/ymj.2017.58.3.479.

Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease

Robinson RA, Amin B, Guest PC.

Adv Exp Med Biol. 2017;974:21-48. doi: 10.1007/978-3-319-52479-5_2.

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial

Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, Jung Y, Maldjian J, Whitlow C, Friedman S.

J Alzheimers Dis. 2017;57(4):1325-1334. doi: 10.3233/JAD-161256.

Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies

Shinohara M, Tachibana M, Kanekiyo T, Bu G.

J Lipid Res. 2017 Jul;58(7):1267-1281. doi: 10.1194/jlr.R075796. Epub 2017 Apr 4.

A phase 3 trial of IV immunoglobulin for Alzheimer disease

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

Neuropsychiatric Symptoms and Neuroimaging Biomarkers in Alzheimer Disease: "Which is the Cart and Which is the Horse?"

Geda YE, Krell-Roesch J, Sambuchi N, Michel BF.

Am J Geriatr Psychiatry. 2017 Jul;25(7):694-696. doi: 10.1016/j.jagp.2017.03.007. Epub 2017 Mar 16.

Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease

Kasai T, Kondo M, Ishii R, Tanaka A, Ataka S, Shimada H, Tomiyama T, Mori H, Taylor M, Allsop D, Nakagawa M, Mizuno T, Tokuda T.

PLoS One. 2017 Apr 10;12(4):e0174630. doi: 10.1371/journal.pone.0174630. eCollection 2017.

[Correlation between Alzheimer disease and cataract]

Liu SS, Zhu SQ.

Zhonghua Yan Ke Za Zhi. 2017 Apr 11;53(4):314-316. doi: 10.3760/cma.j.issn.0412-4081.2017.04.016.

How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study

Carapelle E, Serra L, Modoni S, Falcone M, Caltagirone C, Bozzali M, Specchio LM, Avolio C.

Medicine (Baltimore). 2017 Apr;96(16):e5876. doi: 10.1097/MD.0000000000005876.

Applying fluid biomarkers to Alzheimer's disease

Zetterberg H.

Am J Physiol Cell Physiol. 2017 Jul 1;313(1):C3-C10. doi: 10.1152/ajpcell.00007.2017. Epub 2017 Apr 19.

Elucidating the Role of TREM2 in Alzheimer's Disease

Ulrich JD, Ulland TK, Colonna M, Holtzman DM.

Neuron. 2017 Apr 19;94(2):237-248. doi: 10.1016/j.neuron.2017.02.042.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias